A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Specifically, Enhertu (trastuzumab deruxtecan) has been cleared to treat HR-positive, HER2-low metastatic breast cancer – an immunohistochemistry (IHC) score of 1+ or 2+ or negative for in situ ...

Breast cancer classed as HER2-positive – defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease.

Q4 2024 Earnings Call Transcript March 3, 2025 Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.11 ...

Martin Huber; President, Chief Executive Officer, Director; Mersana Therapeutics Inc Brian Deschuytner; Chief Financial Officer, Chief Operating Officer, Senior Vice President; Mersana Therapeutics ...

They found that all HER2-negative breast cancer samples, using the traditional clinical HER2-negative definition of an IHC score of 0, 1+, or 2+ with a negative in situ hybridization (ISH) result, in ...

Assessment of HER2 is recommended in every newly diagnosed case of breast cancer. Immunohistochemistry is the primary option, as long as the cases classified as 2+ or equivocal are re-evaluated by ...

HER2-low status was defined as immunohistochemistry (IHC ... correlated with higher ERBB2 mRNA expression in comparison to HER2-zero tumors, with a mean score of 9.3 vs. 9.1 (p < .001) in WSG-ADAPT ...